Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | inaxaplin (VX-147) - (AMPLITUDE) | Proteinuric kidney disease with two mutations in the APOL1 gene (AMKD) | Phase 3 | Ongoing | oral | Genetic Disorder |
| Vertex Pharmaceuticals Incorporated | VX-661 | Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in minimal CFTR Function | Phase 3 | Trial Discontinued | oral | Genetic Disorder |
| Vertex Pharmaceuticals Incorporated | VX-121/tezacaftor/VX-561 - (SKYLINE-102) | Cystic Fibrosis | Phase 3 | Ongoing | Oral | Respiratory |
| Vertex Pharmaceuticals Incorporated | VX-661 | Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in minimal CFTR Function | Phase 3 | Trial Discontinued | oral | Genetic Disorder |
| Vertex Pharmaceuticals Incorporated | VX-121/tezacaftor/VX-561 - (SKYLINE-102) | Cystic Fibrosis | Phase 3 | Ongoing | Oral | Respiratory |
| Vertex Pharmaceuticals Incorporated | Suzetrigine | Painful Lumbosacral Radiculopathy | Phase 3 | Trial Planned | Oral | Orthopedic |
| Vertex Pharmaceuticals Incorporated | Povetacicept - (OLYMPUS) | Primary Membranous Nephropathy (pMN) | Phase 2/3 | Ongoing | Subcutaneous | Immunology |
| Vertex Pharmaceuticals Incorporated | Povetacicept | Generalized myasthenia gravis | Phase 2 | Trial Planned | Subcutaneous | Neurology |
